Direct Oral Anticoagulants for Stroke and Systemic Embolism Prevention in Patients with Left Ventricular Thrombus

In recent years, direct oral anticoagulants (DOAC) have accumulated evidence of efficacy and safety in various clinical scenarios and are approved for a wide spectrum of indications. Still, they are currently used off-label for left ventricular thrombus owing to a paucity of evidence. For the same r...

Descripción completa

Detalles Bibliográficos
Autores principales: Badescu, Minerva Codruta, Sorodoc, Victorita, Lionte, Catalina, Ouatu, Anca, Haliga, Raluca Ecaterina, Costache, Alexandru Dan, Buliga-Finis, Oana Nicoleta, Simon, Ioan, Sorodoc, Laurentiu, Costache, Irina-Iuliana, Rezus, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866081/
https://www.ncbi.nlm.nih.gov/pubmed/36675819
http://dx.doi.org/10.3390/jpm13010158
Descripción
Sumario:In recent years, direct oral anticoagulants (DOAC) have accumulated evidence of efficacy and safety in various clinical scenarios and are approved for a wide spectrum of indications. Still, they are currently used off-label for left ventricular thrombus owing to a paucity of evidence. For the same reason, there is a lack of guideline indication as well. Our work is based on an exhaustive analysis of the available literature and provides a structured and detailed update on the use of DOACs in patients with left ventricle thrombus. The safety and efficacy of DOACs were analyzed in particular clinical scenarios. As far as we know, this is the first paper that analyzes DOACs in this approach.

Ejemplares similares